Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark
15 août 2024 07h30 HE
|
Avicanna Inc.
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and...
Avicanna Reports Q2 2024
14 août 2024 17h45 HE
|
Avicanna Inc.
Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023Completion of two real world evidence trials on Epidermolysis Bullosa and Musculoskeletal Pain TORONTO, Aug. 14, 2024 (GLOBE NEWSWIRE)...
Avicanna Announces Changes of Auditors
02 août 2024 17h30 HE
|
Avicanna Inc.
TORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore
11 juil. 2024 07h30 HE
|
Avicanna Inc.
This marks the first export into Asia, the 18th international market for Aureus branded products and 21st market for all Avicanna products TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc....
Avicanna Announces Results of Annual General Meeting & Provides Corporate Update
10 juil. 2024 17h30 HE
|
Avicanna Inc.
TORONTO, July 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing,...
Avicanna General Meeting
19 juin 2024 17h30 HE
|
Avicanna Inc.
TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Announces USPTO Issuance of Patent SEDDS Technology
19 juin 2024 07h30 HE
|
Avicanna Inc.
TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna to Present at the Life Science Investor Forum June 20th, 2024
18 juin 2024 07h45 HE
|
Avicanna Inc.
TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
14 mai 2024 07h35 HE
|
Avicanna Inc.
Best Quarterly Results in Company’s History from a Financial Perspective.EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies.Marketing Authorization of Trunerox™...
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
13 mai 2024 07h30 HE
|
Avicanna Inc.
The study conducted at The Hospital for Sick Children evaluated wound healing, pain, and itch.55% of patients enrolled in Study reported improvements in wound healing, 45% displayed wound stability. ...